Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
NCT ID: NCT00393939
Last Updated: 2012-07-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
594 participants
INTERVENTIONAL
2007-02-28
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Sunitinib malate
Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
B
Taxotere
Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sunitinib malate
Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
Taxotere
Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Her-2 negative tumors
Exclusion Criteria
* Clinical presentation of inflammatory carcinoma with no other measurable disease
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Berkely, California, United States
Pfizer Investigational Site
Shreveport, Louisiana, United States
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Burleson, Texas, United States
Pfizer Investigational Site
Cleburne, Texas, United States
Pfizer Investigational Site
Fort Worth, Texas, United States
Pfizer Investigational Site
Mineral Wells, Texas, United States
Pfizer Investigational Site
Weatherford, Texas, United States
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Pergamino, Buenos Aires, Argentina
Pfizer Investigational Site
Burnos Aires, , Argentina
Pfizer Investigational Site
Tweed Heads, New South Wales, Australia
Pfizer Investigational Site
Redcliffe, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Brighton, Victoria, Australia
Pfizer Investigational Site
Malvern, Victoria, Australia
Pfizer Investigational Site
Ringwood East, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Salzburg, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Brasschaat, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Verviers, , Belgium
Pfizer Investigational Site
Surrey, British Columbia, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Kingston, Ontario, Canada
Pfizer Investigational Site
Kingston, Ontario, Canada
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Pereira, Risaralda Department, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca Department, Colombia
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Nový Jičín, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Nantes, , France
Pfizer Investigational Site
Reims, , France
Pfizer Investigational Site
Saint-Cloud, , France
Pfizer Investigational Site
Saint-Priest-en-Jarez, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Tours, , France
Pfizer Investigational Site
Villejuif, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Chemnitz, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Hildesheim, , Germany
Pfizer Investigational Site
Karlsruhe, , Germany
Pfizer Investigational Site
Leverkusen, , Germany
Pfizer Investigational Site
Magdeburg, , Germany
Pfizer Investigational Site
Marburg, , Germany
Pfizer Investigational Site
Oldenburg, , Germany
Pfizer Investigational Site
Ravensburg, , Germany
Pfizer Investigational Site
Rosenheim, , Germany
Pfizer Investigational Site
Würzburg, , Germany
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Kaposvár, , Hungary
Pfizer Investigational Site
Szentes, , Hungary
Pfizer Investigational Site
Dublin, , Ireland
Pfizer Investigational Site
Dublin, , Ireland
Pfizer Investigational Site
Dublin, , Ireland
Pfizer Investigational Site
Galway, , Ireland
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Cattolica (RN), , Italy
Pfizer Investigational Site
Cefalu' (PA), , Italy
Pfizer Investigational Site
Chieti Scalo, , Italy
Pfizer Investigational Site
Lecce, , Italy
Pfizer Investigational Site
Livorno, , Italy
Pfizer Investigational Site
Macerata, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Palermo, , Italy
Pfizer Investigational Site
Pavia, , Italy
Pfizer Investigational Site
Rimini, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Utrecht, , Netherlands
Pfizer Investigational Site
Venlo, , Netherlands
Pfizer Investigational Site
Panama City, Provincia de Panamá, Panama
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Lubin, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Rybnik, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Santa Maria da Feira, , Portugal
Pfizer Investigational Site
Cluj-Napoca, Cluj, Romania
Pfizer Investigational Site
Cluj-Napoca, Cluj, Romania
Pfizer Investigational Site
Craiova, Dolj, Romania
Pfizer Investigational Site
Bucharest, Sector 2, Romania
Pfizer Investigational Site
Kuzmolovo, Vsevolozhsk District, Leningradskaya Oblast', Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Nitra, , Slovakia
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain
Pfizer Investigational Site
Dos Hermanas, Sevilla, Spain
Pfizer Investigational Site
Toledo, Toledo, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Zaragoza, Zaragoza, Spain
Pfizer Investigational Site
Helsingborg, , Sweden
Pfizer Investigational Site
Karlstad, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Uppsala, , Sweden
Pfizer Investigational Site
Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Gaziantep, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Dnipropetrovsk, , Ukraine
Pfizer Investigational Site
Donetsk, , Ukraine
Pfizer Investigational Site
Ivano-Frankivsk, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Lviv, , Ukraine
Pfizer Investigational Site
Cheltenham, Gloucestershire, United Kingdom
Pfizer Investigational Site
Maidstone, Kent, United Kingdom
Pfizer Investigational Site
Manchester, M20 4bx, United Kingdom
Pfizer Investigational Site
Metropolitan Borough of Wirral, Merseyside, United Kingdom
Pfizer Investigational Site
Shrewsbury, Shropshire, United Kingdom
Pfizer Investigational Site
Telford, Shropshire, United Kingdom
Pfizer Investigational Site
Guildford, Surrey, United Kingdom
Pfizer Investigational Site
Worthing, West Sussex, United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6181064
Identifier Type: -
Identifier Source: org_study_id